• Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review

  • Mar 21 2024
  • Duración: 1 h y 2 m
  • Podcast

Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review

  • Resumen

  • Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.
    Más Menos
activate_WEBCRO358_DT_T2

Lo que los oyentes dicen sobre Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.